In tumors, CEBPZ has been proposed as a marker for colorectal and gastric cancers, whereas point and missense mutations have been identified in individuals with acute myeloid leukemia (AML) (Herold et al., 2014), where CEBPZ works as a cofactor to maintain m6A modifications in leukemia cells (Barbieri et al., 2017). Here, CEBPZ is linked to leukemia.